Literature DB >> 22244072

Inhibition of the pore-forming protein perforin by a series of aryl-substituted isobenzofuran-1(3H)-ones.

Julie A Spicer1, Kristiina M Huttunen, Christian K Miller, William A Denny, Annette Ciccone, Kylie A Browne, Joseph A Trapani.   

Abstract

An aryl-substituted isobenzofuran-1(3H)-one lead compound was identified from a high throughput screen designed to find inhibitors of the lymphocyte pore-forming protein perforin. A series of analogs were then designed and prepared, exploring structure-activity relationships through variation of 2-thioxoimidazolidin-4-one and furan subunits on an isobenzofuranone core. The ability of the resulting compounds to inhibit the lytic activity of both isolated perforin protein and perforin delivered in situ by intact KHYG-1 natural killer effector cells was determined. Several compounds showed excellent activity at concentrations that were non-toxic to the killer cells. This series represents a significant improvement on previous classes of compounds, being substantially more potent and largely retaining activity in the presence of serum.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22244072     DOI: 10.1016/j.bmc.2011.12.011

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  The preclinical pharmacokinetic disposition of a series of perforin-inhibitors as potential immunosuppressive agents.

Authors:  M R Bull; J A Spicer; K M Huttunen; W A Denny; A Ciccone; K A Browne; J A Trapani; N A Helsby
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-08-26       Impact factor: 2.441

2.  Preclinical Activity and Pharmacokinetic/Pharmacodynamic Relationship for a Series of Novel Benzenesulfonamide Perforin Inhibitors.

Authors:  Kate H Gartlan; Jagdish K Jaiswal; Matthew R Bull; Hedieh Akhlaghi; Vivien R Sutton; Kylie A Alexander; Karshing Chang; Geoffrey R Hill; Christian K Miller; Patrick D O'Connor; Jiney Jose; Joseph A Trapani; Susan A Charman; Julie A Spicer; Stephen M F Jamieson
Journal:  ACS Pharmacol Transl Sci       Date:  2022-05-31

3.  Isobenzofuranone derivatives exhibit antileishmanial effect by inhibiting type II DNA topoisomerase and inducing host response.

Authors:  Amartya Mishra; Jayaraman Vinayagam; Sourav Saha; Sayan Chowdhury; Somenath Roy Chowdhury; Parasuraman Jaisankar; Hemanta K Majumder
Journal:  Pharmacol Res Perspect       Date:  2014-08-24

4.  Diarylthiophenes as inhibitors of the pore-forming protein perforin.

Authors:  Christian K Miller; Kristiina M Huttunen; William A Denny; Jagdish K Jaiswal; Annette Ciccone; Kylie A Browne; Joseph A Trapani; Julie A Spicer
Journal:  Bioorg Med Chem Lett       Date:  2015-12-07       Impact factor: 2.823

5.  Substituted arylsulphonamides as inhibitors of perforin-mediated lysis.

Authors:  Julie A Spicer; Christian K Miller; Patrick D O'Connor; Jiney Jose; Kristiina M Huttunen; Jagdish K Jaiswal; William A Denny; Hedieh Akhlaghi; Kylie A Browne; Joseph A Trapani
Journal:  Eur J Med Chem       Date:  2017-05-26       Impact factor: 6.514

6.  Benzenesulphonamide inhibitors of the cytolytic protein perforin.

Authors:  Julie A Spicer; Christian K Miller; Patrick D O'Connor; Jiney Jose; Kristiina M Huttunen; Jagdish K Jaiswal; William A Denny; Hedieh Akhlaghi; Kylie A Browne; Joseph A Trapani
Journal:  Bioorg Med Chem Lett       Date:  2016-12-23       Impact factor: 2.823

7.  Exploration of a series of 5-arylidene-2-thioxoimidazolidin-4-ones as inhibitors of the cytolytic protein perforin.

Authors:  Julie A Spicer; Gersande Lena; Dani M Lyons; Kristiina M Huttunen; Christian K Miller; Patrick D O'Connor; Matthew Bull; Nuala Helsby; Stephen M F Jamieson; William A Denny; Annette Ciccone; Kylie A Browne; Jamie A Lopez; Jesse Rudd-Schmidt; Ilia Voskoboinik; Joseph A Trapani
Journal:  J Med Chem       Date:  2013-11-19       Impact factor: 7.446

Review 8.  Inhibition of Pore-Forming Proteins.

Authors:  Neža Omersa; Marjetka Podobnik; Gregor Anderluh
Journal:  Toxins (Basel)       Date:  2019-09-19       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.